Drug intelligence / Profile preview

NNC0113-6861

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Intravenous

Overview

NNC0113-6861 is an experimental antidiabetic drug candidate developed by Novo Nordisk for the treatment of type 2 diabetes mellitus. It is a peptide-based molecule designed to mimic the action of established incretin-based therapies, likely acting as a glucagon-like peptide-1 (GLP-1) receptor agonist to enhance insulin secretion and regulate blood glucose levels. The compound was evaluated in a Phase 0 clinical trial (NCT03824301), which was a candidate selection study assessing the pharmacokinetics of three different 14C-labelled microdoses in healthy male volunteers. This study aimed to characterize the metabolic breakdown and disposition of the drug using radioactive tracking to inform further clinical development decisions.

Other names: [14C]-NNC0113-6861

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NNC0113-6861.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0113-6861.

Explore the full profile